Table 2.
Biomarkers in NSCLC.
| Biomarkers in Nsclc | |||||
|---|---|---|---|---|---|
| Diagnostic Biomarkers in NSCLC | |||||
| Immunohistochemistry | Circulating tumor proteins | ||||
| TTF-1 (Thyroid Transcription Factor-1) | Cytokeratin 19 fragment (CYFRA 21-1) | ||||
| p40 | Carcinoembryonic Antigen (CEA) | ||||
| Napsin A | Squamous cell carcinoma antigen (SCCA) | ||||
| Carbohydrate antigen 125 (CA125) | |||||
| microRNA (miRNA) | |||||
| miR-205 | miR-106a | miR-29b | |||
| miR-375 | miR-125a-5p | miR-375 | |||
| miR-93 | miR-129-3p | miR-7 | |||
| miR-221 | miR-205 | miR-19b-3p | |||
| miR-100 | miR-21 | miR-199a-5p | |||
| Predictive Biomarkers in NSCLC | |||||
| Targeted Therapy | For Inmunotherapy | Novel predictive biomarkers | |||
| Biomarker | Therapy | Biomarker | Antibody | Targered therapy | Inmunotherapy |
| EGFR | Afatinib | PD-1 | Atezolizumab | KRAS | Exosome PD-L1 |
| Erlotinib | Pembrolizumab | FGFR1 | m6A methylation | ||
| Gefitinib | Durvalumab | DDR2 | SFTA2 | ||
| Osimertinib | Nivolumab | HER2 | TIL’s | ||
| TIM-3 | |||||
| ROS1 | Entrectinib | TMB | |||
| Ceritinib | |||||
| Crizotinib | |||||
| ALK | Alectinib | ||||
| Crizotinib | |||||
| Lorlatinib | |||||
| MET | Tepotinib | ||||
| Capmatinib | |||||
| RET | Selpercatinib | ||||
| Praseltinib | |||||
| BRAF | Trametinib | ||||
| Dabrafenib+ | |||||
| NTRK (1,2,3) | Larotrectinib | ||||